About Rejoni
Rejoni is a Healthcare company based in Bedford (United States) founded in 2020. It operates as a therapeutics for womens health conditions are developed using innovative hydrogels. Rejoni has raised $66.25 million across 3 funding rounds from investors including Sparta Group, Sparta Capital and CHV. Rejoni offers products and services including Juveena Hydrogel. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases. Its competitors include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Gameto and ClearFlow and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
Rejoni was founded in 2020 and is based in Bedford, United States. Focus is placed on the biotechnology sector, where therapeutics for womens health conditions are developed. Operations center on creating a soft gel-like material named Juveena Hydrogel, which is designed to prevent intrauterine adhesions after uterine surgery. This approach addresses post-surgical complications in gynecological care through targeted medical interventions.
- Headquarters Bedford, United States
- SectorsHealthcare
- Website rejoni.com
- Total Equity Funding$66.25M (USD)
in 3 rounds
- Latest Funding Round$25M (USD), Series B
Jun 2026
- InvestorsSparta Group
& 9 more
Products & Services of Rejoni
Rejoni offers a comprehensive portfolio of products and services, including Juveena Hydrogel.
Gel to prevent intrauterine adhesions after uterine surgery procedures.
Funding Insights of Rejoni
Rejoni has successfully raised a total of $66.25M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $66.25M
- Total Rounds 3
- Last Round Series B — $25M
- First Round $15M
(Sep 2020)
- Investors Count 10
All 3 funding rounds of Rejoni with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $25M | Series B | – | – | |
| Feb 2023 | $26.25M | Series B | – | CHV | |
| Sep 2020 | $15M | Series B | – | Ascension Ventures |
10 investors in total: 10 institutional.
Investors in Rejoni
Rejoni has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Sparta Group, Sparta Capital and CHV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | chv.vc | - | |
Strategic investments in healthcare technologies and data innovations. | – | ascensionventures.org | - | |
Delos Capital is engaged in private equity and financial advisory services. | – | deloscap.com | New York City, United States | |
- | – | amedventures.com | - | |
Investment in medical device innovation is facilitated by Iyengar Capital. | – | iyengarcap.com | Clayton, United States | |
Venture capital investments are directed toward therapeutics and medtech startups. | – | deloscapital.com | Hong Kong, China | |
- | – | femhealthventures.com | - | |
Energy-saving technologies are supplied by Sparta Group. | 1988 | spartagroup.ca | Toronto, Canada | |
Environmental technologies and e-waste recycling solutions are provided. | 1988 | spartacapital.com | Toronto, Canada | |
- | – | clavystbio.com | - |
Investor details for Rejoni
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rejoni
3 people are tracked at Rejoni (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Christina Young | Head of Operations | Leadership |
Jonathan Bissett | Senior Director Clinical Operations | Leadership |
Kathryn Jenkins | Clinical Project Manager | Team |
Complete people profiles for Rejoni
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rejoni
3 dated milestones of Rejoni across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Rejoni is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series B, of $25.0M.
Competitors of Rejoni
Rejoni has 8 listed competitors in our database, 6 of them funded. They include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Gameto and ClearFlow, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sproutpharmaceuticals.com | 2011 | Raleigh, United States | $185.16M | 31 | Drugs for hypoactive sexual desire disorder in women are developed. | |
| obseva.com | 2012 | Geneva, Switzerland | $94.7M | – | Therapeutics for women's reproductive health and pregnancy are developed. | |
| hopemedinc.com | 2018 | Shanghai, China | $56M | – | Monoclonal antibodies are developed for treating multiple diseases. | |
| gametogen.com | 2020 | United States | $127M | – | Therapeutics for fertility and menopause treatments are developed. | |
| clearflow.com | 2007 | Irvine, United States | $52.62M | 10 | Anti-clogging technologies for medical drainage catheters are developed. | |
| cordis.com | 1957 | Fremont, United States | – | 5 | Cardiovascular and endovascular devices are developed and marketed by Cordis. | |
| peters-surgical.com | 1926 | Bobigny, France | – | 145 | Surgical disposables and medical supplies are developed and distributed globally. | |
| naari.co | 2007 | Noida, India | $18.98M | 195 | Women care medicines are manufactured by Naari in India. |
Detailed competitors of Rejoni
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Women's Health & Fertility
10 companies that operate in the same segment as Rejoni (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 861 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rejoni
Complete news archive for Rejoni
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rejoni
Rejoni was founded in 2020.
Rejoni is headquartered in Bedford, United States.
Rejoni is a funded company, having raised a total of $66.25M across 3 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Sep 2020.
Rejoni was founded in 2020 and is based in Bedford, United States. Focus is placed on the biotechnology sector, where therapeutics for womens health conditions are developed. Operations center on creating a soft gel-like material named Juveena Hydrogel, which is designed to prevent intrauterine adhesions after uterine surgery. This approach addresses post-surgical complications in gynecological care through targeted medical interventions.
Rejoni's top competitors include Sprout Pharmaceuticals, Hope Medicine and Gameto.
Rejoni offers Juveena Hydrogel.
Rejoni has 10 investors. Key investors include Sparta Group, Sparta Capital, CHV, Ascension Ventures, and Delos Capital.